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PURPOSE: The aim of this study was to assess the quality of life (QOL) of Treated 
head and neck cancer patients after 1 year; and to identify the various predictors of QOL 
 
METHODS:  HRQOL was examined by the European Organization for Research and 
Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-H&N35 and a study-speciﬁc 
(Cancer Institute QLQ) questionnaire, after 1 year Post treatment in 150 patients at the 
tertiary care hospital in South India. Changes in HRQOL were assessed. Frequency 
tables were used to describe the data. Chi square test was used to test the difference 
between 2 factors measured on nominal scale. Mann Whitney U test were employed to 
test for differences between factors measured on ordinal scale were used to examine if 
baseline characteristics had any inﬂuence towards HRQOL changes. 
 
RESULTS: A total of 150 patients were recruited in the study. The study group (n=150) 
consisted of 48 females (32%) and 102 males (68%). The age of the treated patients 
ranged from 17-77yrs. Majority of patients had an average overall quality of life. Role 
functioning and cognitive functions had a significant statistical significant difference 
among patients of various tumour sites. The median value for role function of  laryngeal 
cancer patients was higher (83.33%).The median values for cognitive functions was the 
same in patients of various tumour sites. Dyspnea had a statistical  significant difference 
among patients of various tumour sites. Financial difficulties was found in all cancer 
patients. The median value was found higher in laryngeal cancer patients 100 (range 
66.66-100) with a statistically significant p value of 0.007. The median values of Pain 
(HNPA) and Senses problems (HNSE) were similar i.e 33.33 among the patients of 
various tumour sites. There was a statistical significant difference, p value (p value for 
HNPA-0.046 and p value for HNSE was 0.029). The median values for Trouble with 
Social eating (HNSO) was found higher in patients with cancer nasopharynx and 
hypopharynx with a value of 33.33, statistically significant difference (p value of 
0.015). The median value for dry mouth (HNDR) was found similar in all patients of 
various tumour sites with a median value of 66.66 and a statically significant difference 
(p value <0.001). Social function had a significant difference among patients of two age 
groups with a p value of 0.042. The median values for symptom scales such as Pain 
(PA) was found similar in both age groups with a value of 33.33 that was statistically 
significant p value 0.023. The median values for symptom scale Nausea vomiting (NV) 
was found high in younger population with a value of 66.66, with statistically significant 
with a p value of <0.009.The median values for symptom scales such as Dyspnoea (DY) 
and insomnia (SL) were found similar with a value of 33.33 with a statistical significant 
difference among these two different age groups with a p value of 0.022 for dyspnoea 
and 0.045 for insomnia. With respect to sex, fatigue had a statistical significant 
difference among males and females with a p value of 0.036 
 
 
 
 
  
  
 
 
 
 among patients. There was no significant statistical difference in the quality of life 
among the patients of different age, gender, various tumor sites and tumor stages in 
head and neck patients. 
Conclusion: Most of the domains of quality of life almost returned to normal levels post 
1 year of treatment except  social functions, dyspnoea, financial instabilities, senses 
problems, xerostomia, Nausea  vomiting ,insomnia and social eating. Early intervention 
addressing eating issues, swallowing problems, pain management and psychosocial 
counselling will be crucial in improving quality of life in cancer survivors. The quality 
of life was found better in males and in elderly population though not statistically 
significant. 
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